Leaders

Alex Loukas
Co-Founder and Co-CSO

Dr Paul Giacomin
Co-Founder and Co-CSO

Dr Keats Nelms
CEO
Investment Team
challenges
Autoimmune and inflammatory diseases like IBD and Type 2 Diabetes affect hundreds of millions globally, yet existing treatments are narrow in scope, carry debilitating side effects, and offer limited long-term efficacy. The unmet need for safer, more effective biologics remains enormous.
solution
Parasitic helminths have co-evolved with their human hosts for millions of years, developing proteins that quietly suppress immune overreaction without causing harm. Macrobiome has built a proprietary library of these helminth-derived proteins and is mining it to develop a new class of biologics for IBD, Type 2 Diabetes, and wound healing — treatments inspired by nature rather than synthesised from scratch.
You might also like
For founders
Building for the systems that matter? Pitch us.
We back founders turning breakthrough science into category-defining companies.
For investors
Invest with Main Sequence
Access Australia's deep tech frontier alongside us.






